In both FGFR2 fusion+ ICC models tested (ICC13-7 and ICC21), combination treatment potentiated cell growth arrest compared to FGFR inhibitor alone (Supplementary Fig. 8e). The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.